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Abstract
Background: Increasing evidence supports the association of CTNND1 with tumor development and progression.
However, the mechanism and clinical significance of CTNND1 deregulation in hepatocellular carcinoma (HCC)
remains unknown. In this study, we aim to investigate the role of CTNND1 in HCC.
Methods: qRT-PCR and immunohistochemical analyses were used to measure the levels of CTNND1 in HCC
specimens and HCC cell lines. CTNND1 and shCTNND1 were transfected into HCC cell lines to investigate its role in
HCC. Cell migration and invasion were measured by Transwell and Matrigel analyses in vitro. In vivo metastasis
assays were performed in SCID mice.
Results: In clinical HCC samples, we found that CTNND1 expression was significantly up-regulated in cancer lesions
compared with paired normal liver tissues. By silencing or overexpressing CTNND1 in HCC cells, we found that
CTNND1 could promote cell proliferation, migration, and invasion in vitro. An in-vivo assay showed that CTNND1
dramatically promoted HCC cell tumor formation and metastasis. Moreover, CTNND1 promoted HCC metastasis, at
least in part, by indirectly enhancing Wnt/β-catenin signaling. Consistent with these results, the expression of
CTNND1 was positively correlated with β-catenin, WNT11, Cyclin D1, and BMP7 expression in human HCC
specimens.
Conclusions: Our study provides evidence that CTNND1 functions as a novel tumor oncogene in HCC, and may be
a potential therapeutic target for HCC management.
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Background
Hepatocellular carcinoma (HCC) is the third leading cause
of cancer deaths worldwide [1–3]. The vast majority of
HCCs arise in the context of chronic liver injury, inflam-
mation, and hepatocyte proliferation provoked by different
etiologies [4, 5]. HCCs have a highly variable clinical
course, and include several subgroups with distinct
pathways of hepatocarcinogenesis [6]. These processes
share common mechanisms with embryogenesis and can
be considered as an aberrant form of organogenesis [7, 8].
Surgical resection and liver transplantation are available
options for the treatment of early-stage HCC; however,
the prognosis of HCC remains poor because of a high
level of tumor invasiveness, frequent intrahepatic spread,
extrahepatic metastasis, and resistance to chemotherapy.
Cell - cell contact is initiated and maintained by the
adherens junction (AJ). AJs are complexes that are lo-
cated at the basolateral membrane, and are composed of
classical cadherins [9]. The cadherin cytoplasmic domain
directly interacts with CTNND1 (δ-catenin) and β-
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catenin (CTNNB1). Together with α-catenin
(CTNNA1), which binds to β-catenin and links the AJ
to the actin cytoskeleton, they form the core AJ complex
[10]. Accumulating evidence has revealed that the Arma-
dillo catenins are multifunctional nucleo-cytoplasmic
shuttling proteins that regulate gene expression via
interaction with DNA-binding transcriptional factors
[10]. This activity is best illustrated by β-catenin, which
is translocated into the nucleus, where it functions as a
co-transcriptional factor in Wnt/β-catenin signaling. In
contrast to β-catenin, the role of CTNND1 has been less
elucidated. CTNND1 first attracted attention when the
known transcriptional factor Kaiso was identified as a
CTNND1-specific binding partner [11]. Kaiso inhibits β-
catenin/TCF activation of target genes, and CTNND1
inhibits Kaiso activity. Thus, it is now thought that the
Kaiso/CTNND1 complex is a modulator of the canon-
ical Wnt/β-catenin signaling pathway [11]. Recently, a
large amount of data has implicated CTNND1 in the
regulation of cancer development and progression [12–
14]. CTNND1 can function as an oncogene that drives
migration and anchorage independence, both of which
are established hallmarks of metastatic cancer [15, 16].
These results suggest that CTNND1 plays a role in the
oncogenesis of some malignancies. However, whether
CTNND1 expression contributes to HCC development
and progression is not known.
In the present study, we sought to determine whether
and, if so, how CTNND1 regulates the growth and inva-
sion of HCC cells. We found that CTNND1 expression
was significantly up-regulated in cancer lesions compared
with paired normal liver tissues. By silencing or overex-
pressing CTNND1 in HCC cells, we found that CTNND1
could promote cell proliferation, migration, and invasion
in vitro. An in-vivo assay showed that CTNND1 dramatic-
ally promoted HCC cell tumor formation and metastasis.
Moreover, CTNND1 promoted HCC metastasis, at least
in part, by indirectly interacting with Wnt/β-catenin to
enhance Wnt/β-catenin signaling. Consistent with these
results, the expression of CTNND1 was positively corre-
lated with β-catenin, WNT11, Cyclin D1, and MMP7 ex-
pression in human HCC specimens. Our study provides
evidence that CTNND1 functions as a novel tumor onco-




Lipofectamine 2000 transfection and Trizol LS reagents
were purchased from Invitrogen (Grand Island, NY, USA).
Antibodies against CTNND1, WNT11, β-catenin, Cyclin
D1, MMP7, and Kaiso were purchased from Abcam
(Cambridge, MA, USA). E-cadherin, N-cadherin, vimen-
tin, and β-actin antibodies were from Cell Signaling
Technology (Danvers, MA, USA). Anti-α-catenin anti-
body was from BD (Franklin Lakes, NJ, USA).
Patients and specimens
Twenty-six tumor and para-cancerous tissues, which
were used for qRT-PCR analysis, were randomly col-
lected from HCC patients who underwent curative re-
section with informed consent between 2013 and 2014
at the Department of Laparoscopic Surgery, First Affili-
ated Hospital of Guilin Medical University. All tissues
were collected immediately upon resection of the tumors
in the operating theater, transported in liquid nitrogen,
and then stored at -80 °C. Another 289 hepatocellular
carcinoma tissues, which were used for immunohisto-
chemical analysis, were randomly collected from HCC
patients who underwent curative resection with in-
formed consent between 2007 and 2014 at the Depart-
ment of Hepatobiliary Surgery, First Affiliated Hospital
of Guilin Medical University. Tumor staging was based
on the 6th edition of the tumor-node-metastasis (TNM)
classification of the International Union Against Cancer.
The clinicopathologic characteristics of the 289 hepato-
cellular carcinoma tissues are summarized in Table 1.
Follow-up data were summarized at the end of March
2015, with a median observation time of 66.8 months.
Study protocols were approved by the Hospital Ethics
Committee of Guilin Medical University, and written in-
formed consent was obtained from patients based on the
Declaration of Helsinki.
Histological and immunohistochemical analysis
The normal human liver tissues, human tumor tissues,
and lungs dissected from mice were fixed in 4 % parafor-
maldehyde in phosphate-buffered saline (PBS) overnight
and subsequently embedded in paraffin wax. Sections
cut at a thickness of 4 μm were stained with
hematoxylin and eosin for histological analysis. Immu-
nohistochemical analysis was performed for different
markers in these arrays as described previously. The pro-
portion of stained cells (low, <30 % staining; high, ≥30 %
staining) was semiquantitatively determined following
published protocols [17, 18].
Cell culture
HCC cells (ATCC, Manassas, VA, USA) were cultured
under the following conditions: SNU-449, HCCLM3,
HepG2, SK-Hep-1, and MHCC97H cell lines were cul-
tured using 10 % fetal bovine serum (Invitrogen) in
RPMI-1640 (Invitrogen). The HL7702 cell line was cul-
tured using 10 % fetal bovine serum in Dulbecco's modi-
fied Eagle medium (Invitrogen). Cell culture was
according to the manufacturer’s protocol. All the cell
lines were grown at 37 °C in a 5 % CO2/95 % air atmos-
phere, and were revived every 3 to 4 months.
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Establishment of CTNND1 stable expression and
knockdown cell lines
Retroviral constructs containing human pBabe-CTNND1
cDNA and pSuper.retro.puro with shRNA against
human CTNND1 were prepared as described previously
[17, 19]. The generation of retrovirus supernatants and
transfection of hepatocellular carcinoma cells were con-
ducted as described previously [17, 20]. The expression
of CTNND1 was confirmed by qRT-PCR and Western
blotting analysis.
MTT assay
The transfected cells were seeded in 96-well plates at
a density of 3× 103 cells/well. MTT solution (20 μ of
5 mg/ml MTT) was added to each well (for a total
volume of 250 μl), and the plates were incubated for
4 h at 37 °C. Following the removal of the culture
medium, the remaining crystals were dissolved in
DMSO, and the absorbance was measured at 570 nm
using a microplate reader. Cell proliferation was
assessed daily for four consecutive days.
Wound-healing assay
Cells were seeded in 6-cm culture plates. Cell mono-
layers were wounded by scratching with sterile plastic
200-μl micropipette tips, and were photographed using
phase-contrast microscopy. The migration distance of
each cell was measured after the photographs were con-
verted to Photoshop files.
Cell invasion and motility assays
Invasion of cells was measured in Matrigel-coated (BD,
Franklin Lakes, NJ, USA) Transwell inserts (6.5 mm, Co-
star, Manassas, VA, USA) containing polycarbonate fil-
ters with 8-μm pores as detailed previously [21, 22]. The
inserts were coated with 50 μl of 1 mg/ml Matrigel
matrix according to the manufacturer’s recommenda-
tions. Cells (2 × 105) in 200 μl of serum-free medium
were plated in the upper chamber, and 600 μl of medium
with 10% fetal bovine serum was added to lower well.
After a 24-h incubation, cells that had migrated to the
lower surface of the membrane were fixed and stained.
For each membrane, five random fields were counted
at × 10 magnification. Motility assays were similar to
Matrigel invasion assays except that the Transwell insert
was not coated with Matrigel.
Western blotting
Cells were lysed in lysis buffer and total protein contents
were determined by the Bradford method. Proteins (30
μg) were separated by reducing SDS-PAGE, and probed
with specific antibodies. Blots were washed and probed
with respective secondary peroxidase-conjugated anti-
bodies, and the bands were visualized by chemolumines-
cence (Amersham Biosciences, Shanghai, China).
Table 1 CTNND1 staining and clinicopathologic characteristics
of 289 hepatocellular carcinoma patients
Variables CTNND1 staining Total Pa
Low High
Age (y) 0.667
≤ 50 89 (77 %) 27 (23 %) 116
> 50 131 (76 %) 42 (24 %) 173
Sex 0.262
Male 163 (69 %) 27 (31 %) 235
Female 42 (78 %) 12 (22 %) 54
HBsAg 0.231
Negative 53 (65 %) 28 (35 %) 81
Positive 151 (73 %) 57 (27 %) 208
HCV 0.135
Negative 185 (76 %) 57 (24 %) 242
Positive 31 (66 %) 16 (34 %) 47
AFP 0.634
≤ 20 64 (69 %) 27 (31 %) 93
> 20 136 (68 %) 60 (32 %) 196
γ-GT(U/L) 0.187
≤ 54 113 (81 %) 26 (19 %) 139
> 54 110 (73 %) 40 (27 %) 150
Liver cirrhosis 0.766
No 41 (66 %) 22 (34 %) 62
Yes 159 (70 %) 68 (30 %) 227
Tumor diameter (cm) 0.028
≤ 5 178 (70 %) 77 (30 %) 255
> 5 15 (44 %) 19 (56 %) 34
Microvascular invasion <0.001
Absence 92 (80 %) 23 (20 %) 115
Present 63 (36 %) 111 (64 %) 174
Tumor encapsulation 0.196
Complete 83 (62 %) 50 (38 %) 133
None 91 (58 %) 65 (42 %) 156
Tumor differentiation <0.001
I + II 135 (71 %) 56 (29 %) 191
III + IV 31 (32 %) 67 (68 %) 98
TNM stage 0.307
I 161 (69 %) 73 (31 %) 234
II + III 32 (58 %) 23 (42 %) 55
Abbreviations: HBsAg hepatitis B surface antigen; AFP α-fetoprotein; γ-GT γ-
glutamyl transferase; TNM, tumor-nodesmetastasis
a p-value < 0.05 was considered statistically significant. p-values were
calculated using the Pearson chi-square test
Tang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:82 Page 3 of 17
Confocal immunofluorescence microscopy
Cell lines were plated onto culture slides (Costar, Ma-
nassas, VA, USA). After 24 h, the cells were rinsed with
PBS and fixed with 4 % paraformaldehyde in PBS. Cell
membranes were permeabilized using 0.5 % Triton X-
100. The cells were then blocked for 30 min in 10 %
BSA in PBS, and then incubated with primary antibodies
in 10 % BSA overnight at 4 °C. After three washes in
PBS, the slides were incubated for 1 h in the dark with
FITC-conjugated secondary goat anti-mouse, or goat
anti-rabbit antibodies (Invitrogen). After three further
washes, the slides were stained with DAPI for 5 min to
visualize the nuclei, and were examined using a Carl
Zeiss confocal imaging system (LSM 780; Carl Zeiss,
Jena, Germany).
qRT-PCR
Total RNA was extracted using Trizol reagent, and
cDNA was synthesized using SuperScript-Reverse Tran-
scriptase (Invitrogen). qRT-PCR and data collection were
performed with an ABI PRISM 7900HT sequence detec-
tion system. The primers used for the amplification of
the indicated genes are available upon request.
Gene expression profiling
Total RNA quality and quantity were determined using
an Agilent 2100 Bioanalyzer and NanoDrop ND-1000.
Affymetrix HU U133 plus 2.0 arrays were used accord-
ing to the manufacturer’s protocol. The data were ini-
tially normalized by robust multiarray average (RMA)
normalization algorithms in the expression console soft-
ware (Affymetrix). Significantly altered genes between
CTNND1-overexpressing cells and the control cells were
considered by scatter plots and the genes up- and down-
regulated by ≥5-fold. Clustering analysis was done using
a gene list by Gene Cluster v3.0 software, and heat maps
were visualized using Java TreeView v1.1.4r3 software.
Gene-set enrichment analysis was carried out using
ConceptGen. Gene sets were either obtained from Con-
ceptGen or from published gene signatures.
In-vivo tumor growth and metastasis
Nude mice were purchased from the Shanghai Slac La-
boratory Animal Co. Ltd., and were maintained in
microisolator cages. All animals were used in accordance
with institutional guidelines, and the current experi-
ments were approved by the Use Committee for Animal
Care. For subcutaneous inoculation, different numbers
of tumor cells were resuspended in PBS medium with 50
% Matrigel, and were inoculated subcutaneously into the
8-week-old nude mice. The tumors were measured
weekly, and the tumor volume was calculated according
to the formula: length × width2/2. The mice were killed
40 days after the inoculation. For metastasis assays, cells
were resuspended in PBS at a concentration of 1x107
cells ml-1. Cell suspension (0.1 ml; 1x106 cells) was
injected into tail veins of nude mice. All of the mice
were killed by CO2 60 days after inoculation.
Statistical analysis
Results were analyzed with SPSS13.0 statistical software.
Correlation between CTNND1 expression and clinico-
pathologic parameters was evaluated using the Chi-square
(χ2) test, and quantitative variables were analyzed by the
independent t test. The survival probability was estimated
by the Kaplan–Meier method, and the comparison of sur-
vival curves between groups was done with the log-rank
test. The statistical significance of the differences between
mean values was determined by P <0.05.
Results
CTNND1 is highly expressed and correlated with distant
metastasis in HCCs
To investigate whether CTNND1 might be involved in
HCC, the mRNA expression level of CTNND1 in HCC
tissues and its matched normal adjacent tissues was de-
termined by qRT-PCR in 37 samples (Fig. 1a). Compared
with normal tissues, HCC specimens showed overex-
pression of CTNND1 (Fig. 1b). We then analyzed
CTNND1 expression in HCCs without or with invasive
property; we found that CTNND1 mRNA overexpression
was significantly correlated with invasive property in
HCC tissues (Fig. 1c). As shown in Additional file 1:
Figure S1, the expression level of CTNND1 protein
(Fig. 1d and e) and mRNA (Fig. 1f ) in invasive HCC cell
lines was higher than that in the non-invasive HCC cell
lines. These data demonstrate that the upregulation of
CTNND1 might be relevant to the invasive properties of
HCC.
We examined CTNND1 protein expression in more
HCC samples by IHC (Fig. 2a). We observed that the
level of CTNND1-positive cells was markedly higher in
HCC tissues than in the normal liver tissues (Fig. 2b).
Most importantly, CTNND1 overexpression was consist-
ently significantly correlated with distant metastasis in
these HCC samples (Fig. 2b). To investigate the relation-
ship between CTNND1 expression and clinicopathologi-
cal parameters in the 289 cases with HCC, these cases
were first divided into two subgroups: “low CTNND1
expression” and “high CTNND1 expression” as defined
in the immunohistochemistry section of “Materials and
methods”. Significant correlations were found between
CTNND1 expression and tumor diameter, microvascular
invasion, and tumor differentiation. There were no stat-
istical correlations between CTNND1 expression and
other clinicopathological parameters, such as patient
age, gender, and HBsAg (Table 1). The association be-
tween CTNND1 expression in HCC and the survival
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Fig. 1 CTNND1 is highly expressed in HCC tissues and HCC cell lines. a CTNND1 mRNA expression was analyzed by quantitative RT-PCR in tumors
and adjacent tissues in 37 samples. b Comparison of the expression levels of CTNND1 mRNA in adjacent normal tissues and HCC. c Comparison
of the expression levels of CTNND1 mRNA in non-invasive and invasive HCC tissues. d CTNND1 protein expression was analyzed by Western
blotting in HL7702, SNU-449, HCCLM3, HepG2, SK-Hep-1, and MHCC97H cell lines. e Comparison of the expression levels of CTNND1 protein in
non-invasive and invasive cell lines. f Comparison of the expression levels of CTNND1 mRNA in non-invasive and invasive cell lines. **, P < 0.01 is
based on the Student t test. All results are from three independent experiments. Error bars, SD
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time of selected patients was analyzed by Kaplan–Meier
survival analysis (Fig. 2c). The median overall survival
time of the high CTNND1 expression group was signifi-
cantly shorter than that of the low CTNND1 expression
group (P = 0.0022). In addition, we analyzed the expres-
sion of CTNND1 with TCGA data, and found that the
overall survival time of the high CTNND1 expression
group was also significantly shorter than that of the low
CTNND1 expression group in TCGA data (Additional file
1: Figure S1). Together, these results indicate a functional
role of CTNND1 in the aggressive behavior of HCC.
CTNND1 promotes the proliferative capacity of HCC cells
both in vitro and in vivo
In order to test the oncogenic activity of CTNND1 in
HCC, we retrovirally established stable silencing of
CTNND1 in SK-Hep-1 cells and overexpression of
CTNND1 in SNU-449 cells. The levels of CTNND1 in
these resultant cell lines were verified by Western blot-
ting (Fig. 3a and c) and qRT-PCR (Fig. 3b and d).
Compared to vector-only controls, silencing of
CTNND1 in SK-Hep-1 cells significantly reduced cell
proliferation by the MTT assay (Fig. 3e), In contrast,
overexpression of CTNND1 in SNU-449 cells signifi-
cantly increased cell proliferation (Fig. 3f ). To extend
our in-vitro observations, we investigated whether
CTNND1 could regulate tumorigenic capacity of HCC
cells in vivo. SK-Hep-1-shCTNND1 #1 and SNU-449-
CTNND1 cells, and their corresponding control cells,
were subcutaneously injected into nude mice. As ex-
pected, silencing of CTNND1 in the typically aggressive
SK-Hep-1 cells led to a dramatic decrease in tumor vol-
ume and weight (Fig. 3g and h). In contrast, SNU-449-
CTNND1 cells grew more rapidly at the implantation
Fig. 2 CTNND1 is correlated with distant metastasis in HCC tissues. a CTNND1 protein expression was analyzed by immunohistochemical analysis
in 289 cases of HCC tissue, and representative results are shown. b Semiquantification of CTNND1 expression in normal tissues, and non-invasive
and invasive HCC tissues. c The association between CTNND1 expression in HCC and the survival time of selected patients was analyzed by
Kaplan–Meier survival analysis. Scale bars, 50 μm (upper) and 20 μm (lower) in C. **, P < 0.01 is based on the Student t test. All results are from
three independent experiments. Error bars, SD
Tang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:82 Page 6 of 17
Fig. 3 (See legend on next page.)
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site than the control cells (Fig. 3i and j). Taken together,
these results suggest that CTNND1 is an important
regulator of proliferation in HCC cells.
CTNND1 promotes migratory and invasive capacities of
HCC cells in vitro and metastasis in vivo
The effect of CTNND1 on cell migration was first
assessed using a wound-healing assay. Silencing
CTNND1 dramatically reduced the migratory and inva-
sive capacity of SK-Hep-1 cells (Fig. 4a and b). In con-
trast, SNU-449-CTNND1 cells had significantly faster
closure of the wound area compared to their control
cells (Fig. 4c). This result was confirmed using a Boy-
den's chamber assay (Fig. 4d). Moreover, Huh7-pBabe-
CTNND1 and HepG2-pBabe-CTNND1 cells showed a
greater degree of invasion through Matrigel (Fig. 4d).
These results indicate that CTNND1 promotes migra-
tory and invasive behavior in HCC cells.
We then investigated the functional relevance of
CTNND1 to metastasis in vivo. SK-Hep-1-shCTNND1
#1 and SNU-449-CTNND1 cells, and their correspond-
ing control cells, were injected into nude mice through
the tail vein. CTNND1 overexpression not only signifi-
cantly increased the number of mice with distant metas-
tasis (Fig. 5a), but also dramatically increased the
number of metastatic tumors in the lungs and liver of
each mouse (Fig. 5d and e). Silencing CTNND1 in SK-
Hep1 cells inhibited metastatic behavior, both in terms
of the number of mice with distant metastasis (Fig. 5a)
and the number of metastatic tumors in the lungs and
liver of each mouse (Fig. 5b and c). Therefore, the in-
vivo results further demonstrate the critical role of
CTNND1 in HCC metastasis.
CTNND1 regulates the transition between epithelial and
mesenchymal phenotypes in HCC cells
Next, we observed the morphological changes, and
found that SK-Hep-1-shCTNND1 #1 cells reverted to an
epithelial phenotype as compared to their respective
control cells (Fig. 6a). Consistent with this, silencing of
CTNND1 increased the levels of epithelial markers (E-
cadherin and α-catenin), and decreased the levels of
mesenchymal markers (N-cadherin and vimentin)
(Fig. 6b-d). Conversely, SNU-449-CTNND1 cells
exhibited a fibroblastic morphology (Fig. 6e). This obser-
vation was confirmed by expression analyses of epithelial
and mesenchymal markers. We showed that CTNND1
overexpression decreased the levels of epithelial markers
and increased the levels of mesenchymal markers
(Fig. 6f-h). Taken together, these findings suggest that
CTNND1 plays an important role in regulating EMT-
MET plasticity of HCC cells.
CTNND1 enhances Wnt/β-catenin signaling in HCC cells
To better understand the mechanisms by which
CTNND1 influences HCC development and progres-
sion, we performed gene expression profiling on the SK-
Hep-1-shCTNND1 #1 cell line and its control cells.
Microarray analyses identified a list of genes that were
significantly differentially expressed after CTNND1 si-
lencing, including downregulation of Wnt/β-catenin sig-
naling (Fig. 7a). Furthermore, gene-set enrichment
analysis indicated that gene signatures related to prolif-
eration, neoplasm metastasis and invasion, cell move-
ment and motility, and Wnt/β-catenin signaling were
significantly changed in CTNND1-silenced cells (Fig. 7b),
supporting the idea that CTNND1 regulates prolifera-
tion, EMT, and cancer invasion and metastasis.
These data also led us to hypothesize that CTNND1
exerts these functions via regulation of Wnt/β-catenin
signaling. To test this, we first determined whether β-
catenin is a downstream target of CTNND1 in HCC
cells. Expression of β-catenin in the cells with altered
CTNND1 expression was evaluated by qRT-PCR and
Western blotting. Silencing CTNND1 in SK-Hep-1 cells
dramatically decreased β-catenin mRNA and protein
levels (Fig. 7c and d), whereas SNU-449-CTNND1 cells
exhibited greatly increased β-catenin protein and mRNA
levels (Fig. 7e and f).
It has been shown that CTNND1 regulates Wnt/β-ca-
tenin signaling through its direct interaction with the
transcriptional repressor Kaiso in other cancers [23]. We
next assayed whether CTNND1 directly interacts with
Kaiso. As shown in Fig. 8a, 293T cells were co-
transfected with HA-tagged CTNND1 and Myc-tagged
Kaiso constructs. Immunoprecipitation and subsequent
immunoblot analysis revealed that HA-tagged CTNND1
co-immunoprecipitated with Myc-tagged Kaiso,
(See figure on previous page.)
Fig. 3 CTNND1 promotes proliferative capacity of HCC cells both in vitro and in vivo. a The expression of CTNND1 protein was measured by Western
blotting in the SK-Hep-1-shCTNND1s cell line and theirs control cells. b The expression of CTNND1 mRNA was measured by qRT-PCR in the SK-Hep-1-
shCTNND1s cell line and theirs control cells. c The expression of CTNND1 protein was measured by Western blotting in the SNU-449-CTNND1 cell line
and its control cells. d The expression of CTNND1 mRNA was measured by qRT-PCR in the SNU-449-CTNND1 cell line and its control cells. e The
proliferation of the SK-Hep-1-shCTNND1s cell line and theirs control cells was examined by MTT assay. f The proliferation of the SNU-449-CTNND1 cell
line and its control cells was examined by MTT assay. g Representative images of SK-Hep-1-shCTNND1 #1 or its control cell tumors by subcutaneous
injection. h The weight of tumors formed by SK-Hep-1-shCTNND1 #1 cells or its control cells at harvest. i Representative images of SNU-449-CTNND1
cell or control cell tumors by subcutaneous injection. j The weight of tumors formed by SNU-449-CTNND1 cells or its control cells at harvest.
**, P < 0.01 is based on the Student t test. All results are from three independent experiments. Error bars, SD
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Fig. 4 (See legend on next page.)
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Fig. 4 CTNND1 promotes migratory and invasive capacities of HCC cells in vitro. a The SK-Hep-1-shCTNND1 #1 cell line and its control cells were
subjected to wound-healing assays; the uncovered areas in the wound-healing assays were quantified as a percentage of the original wound area.
b The SK-Hep-1-shCTNND1 #1 cell line and its control cells were subjected to Transwell migration (top), and Matrigel invasion assays (bottom).
Quantification of migrated cells through the membrane and invaded cells through Matrigel of each cell line are shown as proportions of their
vector controls. c The SNU-449-CTNND1 cell line and its control cells were subjected to wound-healing assays. The uncovered areas in the
wound-healing assays were quantified as a percentage of the original wound area. d The SNU-449-CTNND1 cell line and its control cells were
subjected to Transwell migration (top) and Matrigel invasion assays (bottom). Quantification of migrated cells through the membrane and invaded
cells through Matrigel of each cell line are shown as proportions of their vector controls. **, P < 0.01 is based on the Student t test. All results are
from three independent experiments. Error bars, SD
Fig. 5 CTNND1 promotes HCC cell metastasis in vivo. a The total numbers of mice with distant metastasis at 60 days after injection of SK-Hep-1-
shCTNND1 #1 and SNU-449-CTNND1 cells, or their control cells. b The numbers of metastatic foci per section in the lungs of individual mice with
injection of SK-Hep-1-shCTNND1 #1 cells or control cells. c The numbers of metastatic foci per section in the liver of individual mice with injection
of SK-Hep-1-shCTNND1 #1 cells or control cells. d The numbers of metastatic foci per section in the lungs of individual mice with injection of
SNU-449-CTNND1 cells or control cells. e The numbers of metastatic foci per section in the liver of individual mice with injection of SNU-449-
CTNND1 cells or control cells. n = 10 for tail vein injections. **, P < 0.01 is based on the Student t test. All results are from three independent
experiments. Error bars, SD
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Fig. 6 CTNND1 regulates the transition between epithelial and mesenchymal phenotypes in HCC cells. a Representative phase-contrast images of SK-Hep-
1 cells showed that CTNND1 silencing modulated morphologic changes. b Expression of epithelial (E-cadherin and α-catenin) and mesenchymal (N-cad-
herin and Vimentin) markers was analyzed by Western blotting in SK-Hep-1-shCTNND1 #1 cells and control cells. c Expression of epithelial (E-cadherin) and
mesenchymal (N-cadherin) markers was analyzed by immunofluorescence stains in SK-Hep-1-shCTNND1 #1 cells and control cells. d Expression of epithelial
and mesenchymal markers was analyzed by qRT-PCR in SK-Hep-1-shCTNND1 #1 cells and control cells. e Representative phase-contrast images of SNU-449
cells showed that CTNND1 overexpression modulated morphologic changes. f Expression of epithelial (E-cadherin and α-catenin) and mesenchymal
(N-cadherin and Vimentin) markers was analyzed by Western blotting in SNU-449-CTNND1 cells and control cells. g Expression of epithelial (E-cadherin)
and mesenchymal (N-cadherin) markers was analyzed by immunofluorescence stains in SNU-449-CTNND1 cells and control cells. h Expression of epithelial
and mesenchymal markers was analyzed by qRT-PCR in SNU-449-CTNND1 cells and control cells. **, P< 0.01 is based on the Student t test. All results are
from three independent experiments. Error bars, SD
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confirming a physical interaction between the two pro-
teins. It has been shown that β-catenin can regulate
WNT11, Cyclin D1, and MMP7 in many tumor cells
[24], and so we next examined the role of CTNND1-
mediated modulation of these genes. Of note, ectopic
CTNND1 remarkably increased the level of WNT11,
Cyclin D1, and MMP7 at both the protein and mRNA
level (Fig. 8b, e, and f ), whereas silencing CTNND1 in
SK-Hep-1 cells robustly suppressed WNT11, Cyclin D1,
and MMP7 expression (Fig. 8c and d).
To determine whether any correlation existed between
CTNND1 expression and the representative markers of
Wnt/β-catenin signaling in HCC biopsy samples, we ob-
tained RNA from 26 HCC samples and analyzed
CTNND1, β-catenin, WNT11, Cyclin D1, and MMP7
expression using real-time RT-PCR. We found that
CTNND1 expression positively correlated with β-
catenin, WNT11, Cyclin D1, and MMP7 (Fig. 9a–d).
Taken together, these results show that CTNND1 medi-
ates migration, invasion, and metastasis in HCC cells
may partly by activation of Wnt/β-catenin signaling.
Wnt/β-catenin signaling is a mediator for CTNND1-
induced proliferative migration, and invasion in HCC cells
On the basis of the indispensable role of Wnt/β-catenin
signaling in the biologic functions of CTNND1, we over-
expressed β-catenin in SK-Hep-1-shCTNND1 #1 cells
(Fig. 10a) and silenced β-catenin in SNU-449-CTNND1
cells (Fig. 10d). Of note, β-catenin overexpression signifi-
cantly increased proliferation in SK-Hep-1-shCTNND1 #1
cells (Fig. 10b). Moreover β-catenin overexpression signifi-
cantly increased the migration, and invasion of SK-Hep-1-
shCTNND1 #1 cells (Fig. 10c). Meanwhile silencing β-
catenin decreased proliferation in SNU-449-CTNND1
cells (Fig. 10e). Moreover silencing β-catenin in SNU-449-
CTNND1 cells significantly decreased the migration and
invasion (Fig. 10f). Taken together, these results show that
Wnt/β-catenin signaling mediates CTNND1-induced pro-
liferation, migration and invasion in HCC cells.
Discussion
In this research, we delineated for the first time the clin-
ical significance of CTNND1 in HCC and the
Fig. 7 CTNND1 enhances Wnt/β-catenin signaling in HCC cells. a Supervised hierarchical clustering of genes differentially expressed after
CTNND1 silencing in SK-Hep-1 cells. b Gene-set enrichment analysis was carried out using ConceptGen. c Expression of β-catenin protein was
measured by Western blotting in SK-Hep-1-shCTNND1s cells and theirs control cells. d Expression of β-catenin mRNA was measured by qRT-PCR
in SK-Hep-1-shCTNND1s cells and theirs control cells. e Expression of β-catenin protein was measured by Western blotting in SNU-449-CTNND1
cells and control cells. f Expression of β-catenin mRNA was measured by qRT-PCR in SNU-449-CTNND1 cells and control cells. **, P < 0.01 is based
on the Student t test. All results are from three independent experiments. Error bars, SD
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mechanistic role of CTNND1 in regulating HCC cell
proliferation and metastasis. To our knowledge, this is
the first study to show that CTNND1 plays a functional
role in HCC cell proliferation, migration, invasion, and
metastasis. CTNND1 overexpression in HCC cells in-
duced EMT, migration, and invasion traits in vitro and
enhanced metastatic capacity in vivo. In contrast, silen-
cing CTNND1 reversed these events in otherwise ag-
gressive and invasive HCC cells. We also showed that a
mechanistic link exists between CTNND1 and Wnt/β-
catenin signaling through direct interaction with the
transcriptional repressor Kaiso, which subsequently leads
to transcriptional upregulation of Wnt/β-catenin
signaling expression. These results lead us to propose a
model for CTNND1 regulation of EMT, migration, inva-
sion, and metastasis through regulation of Wnt/β-ca-
tenin signaling in HCC cells.
The putative role of CTNND1 as an oncogene in can-
cer development is supported by the observations that
CTNND1 is highly expressed in some tumors relative to
normal tissues [25]. It is well recognized that inactiva-
tion of E-cadherin leads to cytosolic translocation of
CTNND1 in colon, breast, bladder, lung, pancreas, pros-
tate, and stomach tumors, which has been associated
with tumor malignancy [13]. Indeed, studies in breast
and colon cancer indicate that cytosolic CTNND1
Fig. 8 CTNND1 direct interacts with Kaiso and promotes WNT11, Cyclin D1, and MMP7 expression. a 293T cells were co-transfected with HA-
tagged CTNND1 and Myc-tagged Kaiso constructs. Immunoprecipitation and subsequent immunoblot analysis revealed that HA-tagged CTNND1
co-immunoprecipitated with Myc-tagged Kaiso. b Expression of WNT11, Cyclin D1, and MMP7 protein was measured by Western blotting in 293T
cells transfected with HA-tagged CTNND1 and control cells. c Expression of WNT11, Cyclin D1, and MMP7 protein was measured by Western
blotting in SK-Hep-1-shCTNND1 #1 cells and control cells. d Expression of WNT11, Cyclin D1, and MMP7 mRNA was measured by qRT-PCR in
SK-Hep-1-shCTNND1 #1 cells and control cells. e Expression of WNT11, Cyclin D1, and MMP7 protein was measured by Western blot in SNU-449-
CTNND1 cells and control cells. f Expression of WNT11, Cyclin D1, and MMP7 mRNA was measured by qRT-PCR in SNU-449-CTNND1 cells and
control cells. **, P < 0.01 is based on the Student t test. All results are from three independent experiments. Error bars, SD
Tang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:82 Page 13 of 17
controls the invasive phenotype of E-cadherin-deficient
tumor cells [26]. Furthermore, a switch from E-cadherin
expression to P-cadherin, which is associated with a
more invasive behavior, in ovarian and pancreatic cancer
cell lines results in the translocation of CTNND1 to the
cytosol, which in turn induces cell migration by activat-
ing RAC1 and CDC42 [9]. Our study points to a novel
function of CTNND1 in HCC metastasis through pro-
moting two essential characteristics of metastatic disease
in HCCs: migration and invasion [27, 28]. First, HCC
cells expressing high levels of CTNND1 displayed an
EMT phenotype, including the associated stimulatory ef-
fects on in-vitro migration and invasion. Interestingly,
our results indicate that CTNND1 not only promotes
EMT, but silencing of CTNND1 also leads to MET.
Thus, CTNND1 promotes characteristics of migration
that have been proposed as a model for cancer progres-
sion and metastasis. All of these characteristics that are
induced by CTNND1 in vitro culminated in increased
numbers of distant metastases in vivo. These empirical
findings provide a mechanistic framework to explain the
clinical observations that HCC patients with high levels
of CTNND1 in tissue samples have more chance of dis-
tant metastasis, and a significantly shorter overall and
disease-free survival.
The roles of several transcription factors as EMT regu-
lators have been extensively reported [29–31]. In our ef-
fort to elucidate the mechanism by which CTNND1
modulates metastasis traits in HCC cells, we identified
the Wnt/β-catenin signaling as an effective mediator of
CTNND1-induced phenomena. It has been implicated
that oxidative stress in the tumor microenvironment en-
hances canonical Wnt/beta-catenin signaling cascade,
which is involved in the collective cell migration of the
several kinds of solid tumors [32]. In this study, we
found that modulation of CTNND1 expression altered
the Wnt/β-catenin signaling. Previous studies have
shown that CTNND1 can modulate gene expression
through its direct interaction with the transcriptional re-
pressor Kaiso [11]. Kaiso is a member of the BTB family
of transcription factors that can bind to methylated
DNA and/or a specific Kaiso binding sequence. Binding
Fig. 9 CTNND1 expression positively correlates with β-catenin, WNT11, Cyclin D1, and MMP7. a Correlation between CTNND1 expression and β-
catenin expression in HCC biopsy samples was analyzed by correlation analysis. b Correlation between CTNND1 expression and WNT11 expression
in HCC biopsy samples was analyzed by correlation analysis. c Correlation between CTNND1 expression and Cyclin D1 expression in HCC biopsy
samples was analyzed by correlation analysis. d Correlation between CTNND1 expression and the MMP7 expression in HCC biopsy samples was
analyzed by correlation analysis
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of CTNND1 to Kaiso might inhibit its DNA binding and
relieve the repression of its target genes, such as
WNT11, CyclinD1, and MMP7, which have been linked
to non-canonical and canonical WNT-dependent devel-
opmental processes [13]. In accordance with previous
studies, in the present study, we also found that ectopic
CTNND1 remarkably increased the level of β-catenin,
WNT11, Cyclin D1, and MMP7 at both the protein and
mRNA level, whereas silencing CTNND1 robustly sup-
pressed β-catenin, Wnt11, Cyclin D1, and MMP7 ex-
pression in HCC cells. Previous study has found that
activation of canonical Wnt/β-catenin signaling en-
hances in vitro motility of cancer cells by activation of
ZEB1 and other activators of epithelial-to-mesenchymal
transition [33]. Thus, the CTNND1 induced activation
of Wnt/β-catenin signaling promotes HCC cells ETM
formation may partly by ZEB1.
Migration, invasion, and metastasis properties are es-
sential for HCC cells to disseminate from adjacent tis-
sues and to seed new tumors in distant sites. Our results
demonstrate that CTNND1 regulated these essential
characteristics of metastatic disease, and that CTNND1-
induced processes are reversible with the suppression of
CTNND1 expression, thus providing us with a potential
therapeutic option to manipulate CTNND1 levels in
clinical HCC practice.
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